Interferon beta-1b

Generic Name: Interferon beta-1b

Brand Names: Betaferon, Betaseron, Extavia

Drug Type: Biotech

Chemical Formula: -

CAS Number: 145155-23-3

Unique Ingredient Identifier: TTD90R31WZ

Background: Human interferon beta (165 residues), cysteine 17 is substituted with serine. Produced in E. coli, no carbohydrates, MW=18.5kD

Indication: Interferon beta-1b is a drug used for the treatment of relapsing/remitting multiple sclerosis. It has been shown to slow the advance of the disease as well as to decrease the frequency of attacks.

Associated Conditions: Relapsing Multiple Sclerosis (RMS), Secondary Progressive Multiple Sclerosis (SPMS)

Associated Therapies: -

Clinical Trials

IFN-beta 1b and Remdesivir for COVID19

Phase 2

Conditions: Covid19

Interventions: Drug: Interferon beta-1b
Drug: Remdesivir

First Posted Date: 2020-12-01

Last Posted Date: 2020-12-10

Lead Sponsor: The University of Hong Kong

Target Recruit Count: 100

Registration Number: NCT04647695

Locations: 🇭🇰
Queen Mary Hospital, Hong Kong, Hong Kong

IFN Beta-1b and Ribavirin for Covid-19

Phase 2

Conditions: Covid19

Interventions: Drug: Interferon beta-1b
Drug: Ribavirin

First Posted Date: 2020-07-31

Last Posted Date: 2020-07-31

Lead Sponsor: The University of Hong Kong

Target Recruit Count: 96

Registration Number: NCT04494399

Locations: 🇭🇰
The University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong

Dual Therapy With Interferon Beta-1b and Clofazimine for COVID-19

Phase 2

Conditions: COVID-19

Interventions: Drug: Interferon beta-1b
Drug: Clofazimine

First Posted Date: 2020-07-10

Last Posted Date: 2020-07-15

Lead Sponsor: The University of Hong Kong

Target Recruit Count: 81

Registration Number: NCT04465695

Locations: 🇨🇳
The University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong, China

Double Therapy With IFN-beta 1b and Hydroxychloroquine

Phase 2

Completed

Conditions: COVID

Interventions: Drug: Interferon Beta-1B
Drug: Hydroxychloroquine

First Posted Date: 2020-04-17

Last Posted Date: 2020-07-28

Lead Sponsor: The University of Hong Kong

Target Recruit Count: 60

Registration Number: NCT04350281

Locations: 🇭🇰
The University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong

An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to Interferon Beta 1b And The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized Clinical Trial

Phase 2

Completed

Conditions: COVID-19

Interventions: Drug: Hydroxychloroquine
Drug: Lopinavir / Ritonavir
Drug: Interferon Beta-1B
Drug: Interferon Beta-1A

First Posted Date: 2020-04-13

Last Posted Date: 2020-05-05

Lead Sponsor: Shahid Beheshti University of Medical Sciences

Target Recruit Count: 60

Registration Number: NCT04343768

Locations: 🇮🇷
Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences and Health Services, Tehran, Iran, Islamic Republic of

Lopinavir/ Ritonavir, Ribavirin and IFN-beta Combination for nCoV Treatment

Phase 2

Completed

Conditions: Novel Coronavirus Infection

Interventions: Drug: Lopinavir/ritonavir
Drug: Ribavirin
Drug: Interferon Beta-1B

First Posted Date: 2020-02-19

Last Posted Date: 2020-04-15

Lead Sponsor: The University of Hong Kong

Target Recruit Count: 127

Registration Number: NCT04276688

Locations: 🇭🇰
University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong

Evaluate Safety/Tolerability in Portuguese Participants With RRMS Transitioning From Current Therapy

Phase 4

Completed

Conditions: Relapsing Remitting Multiple Sclerosis

Interventions: Drug: interferon beta-1a
Drug: peginterferon beta-1a
Drug: interferon beta-1b

First Posted Date: 2017-06-06

Last Posted Date: 2020-11-25

Lead Sponsor: Biogen

Target Recruit Count: 80

Registration Number: NCT03177083

Locations: 🇵🇹
Hospital Fernando Fonseca, Amadora, Portugal
🇵🇹
Hospital Evora, Evora, Portugal
🇵🇹
Hospital de Braga, Braga, Portugal

and more 12 locations

Natalizumab De-escalation to Interferon-beta-1b in Patients With Relapsing-remitting Multiple Sclerosis

Phase 4

Terminated

Conditions: Relapsing-remitting Multiple Sclerosis

Interventions: Drug: Interferon beta-1b

First Posted Date: 2012-10-05

Last Posted Date: 2014-01-22

Lead Sponsor: Claudio Gobbi

Target Recruit Count: 5

Registration Number: NCT01701856

Locations: 🇨🇭
Ospedale Regionale di Lugano - Civico, Lugano, Ticino, Switzerland

Natalizumab De-escalation With Interferon Beta-1b

Phase 4

Completed

Conditions: Relapsing-remitting Multiple Sclerosis

Interventions: Drug: interferon beta-1b
Drug: Natalizumab

First Posted Date: 2010-06-15

Last Posted Date: 2014-04-17

Lead Sponsor: Claudio Gobbi

Target Recruit Count: 19

Registration Number: NCT01144052

Locations: 🇨🇭
Neurocenter of Southern Switzerland, Ospedale Civico Lugano, Lugano, Ticino, Switzerland

Randomized Study Designed to Look at Disease Progression Using 2 Currently FDA Approved Drugs for the Treatment of RRMS

Phase 4

Terminated

Conditions: Relapsing Remitting Multiple Sclerosis

Interventions: Drug: Glatiramer Acetate
Drug: Betaseron
Drug: Rebif

First Posted Date: 2005-09-20

Last Posted Date: 2010-10-18

Lead Sponsor: Teva Branded Pharmaceutical Products R&D, Inc.

Target Recruit Count: 91

Registration Number: NCT00202995

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy